Delivery of highly lipophilic agents via medical devices

• US 8,257,724 B2
• Filed: 03/22/2006
• Issued: 09/04/2012
• Est. Priority Date: 09/24/1998
• Status: Expired due to Term

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Cromack, Keith R., Toner, John L., Burke, Sandra E., Krasula, Richard W., Schwartz, Lewis B.
• Primary Examiner(s): Packard, Benjamin
• Assistant Examiner(s): Milligan, Adam C
• Application Number:
  US11/386,469
• Publication Number:
  US 20060228452A1
• Time in Patent Office: 2,358 Days
• Field of Search: 424/423, 514/291, 514/449
• US Class Current: 424/423
• CPC Class Codes: A61L 2300/00 Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
• CPC Class Codes: A61L 2300/22 Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Claims

1. A system for delivering a lipophilic agent to a desired area outside a body lumen in order to treat a disease manifesting itself in the body lumen or in organs connected to the body lumen, or to maintain patency of the body lumen, comprising:

a medical device;

a first lipophilic agent capable of penetrating the body lumen wherein the transfer coefficient of said first lipophilic agent is by an amount of at least 5,000 (μ

g/mL)<sup>−

1</sup>, wherein said first lipophilic agent comprises zotarolimus having one of the following structures;

2. The system according to claim 1, further comprising at least one pharmaceutically acceptable carrier or excipient, wherein said medical device is connected to said pharmaceutically acceptable carrier or excipient.

3. The system according to claim 2, wherein said pharmaceutically acceptable carrier or excipient is a polymer.

4. The system according to claim 2, wherein said pharmaceutically acceptable carrier or excipient is an agent.

5. The system according to claim 1, wherein said body lumen comprises at least one of a vessel wall, a coronary artery, esophageal lumen, and a urethra.

6. The system according to claim 5, wherein said first lipophilic agent/medical device is placed adjacent to said body, wherein a therapeutically effective amount of said first lipophilic agent is delivered into said coronary arteries and diffused into the pericardial sac in said drug delivery system.

7. The system according to claim 6, wherein said system provides substantially uniform drug delivery of said lipophilic agent to the myocardium.

8. The system according to claim 6, wherein said system is useful for the treatment of vascular diseases in a subject.

9. The system according to claim 3, wherein said delivery mechanism of said first lipophilic agent includes polymer hydration followed by dissolution of said first lipophilic agent, and wherein said first lipophilic agent is thereafter delivered into said body lumen.

10. The system according to claim 3, wherein said delivery mechanism of said first lipophilic agent includes a lipophilic agent/polymer matrix which controls the elution rate of said first lipophilic agent to said body lumen.

11. The system according to claim 1, further comprises at least one second lipophilic agent.

12. The system according to claim 1, further comprises at least one lipophilic prodrug.

13. The system according to claim 1, further comprises at least one lipophilic penetration enhancer.

14. The system according to claim 13, wherein said lipophilic penetration enhancer is a pharmaceutical agent.

15. The system according to claim 11, wherein the concentration of said second lipophilic agent in combination with said first lipophilic agent is a therapeutically effective amount.

16. The system according to claim 1, further comprises at least one beneficial agent selected from the group consisting of antithrombotics, anticoagulents, antiplatelet agents, antiulcer/antireflux agents, antinauseants/antiemetics and thrombolytic agents.

17. The system according to claim 1, wherein the dosage delivery of said first lipophilic agent into said body lumen ranges from about 15 μ

g/g to about 150 μ

g/g over a period of up to 5 days.

18. The system according to claim 1, wherein the dosage delivery of said first lipophilic agent into said body lumen ranges from about 15 μ

g/g to about 80 μ

g/g over a period from about 5 days to about 15 days.

19. The system according to claim 1, wherein the dosage delivery of said first lipophilic agent into said body lumen ranges from about 5 μ

g/g to about 60 μ

g/g over a period from 15 days to about 28 days.

20. The system according to claim 1, wherein said first lipophilic agent reaches therapeutically significant concentrations in targeted areas in said subject comprising at least one of the distal myocardium, the unstented myocardium, in said subjacent myocardium, in unstented and distal coronary arteries, and maintains those concentrations throughout a 28 day period.

21. The system according to claim 1, wherein said medical device is permanently or temporarily implanted into a subject.

22. The system according to claim 1, wherein said first lipophilic agent is in amorphous form.

23. The system according to claim 1, further comprises a beneficial agent including at least one of antithrombotics, anticoagulants, antiplatelets agents, anti-lipid agents, thrombolytics, antiproliferatives, antiinflammatories, agents that inhibit hyperplasia, smooth muscle cell inhibitors antibiotics, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters, antimitotics, antifibrins, antioxidants, antineoplastics, agents that promote endothelial cell recovery, matrix metalloproteinase inhibitors, antimetabolites, antiallergic substances, viral vectors, nucleic acids, monoclonal antibodies, inhibitors of tyrosine kinase, antisense compounds, oligionucleotides, cell permeation enhancers, and anycombinations thereof.

24. The system according to claim 1, further comprises a beneficial agent including at least one of hypoglycemic agents, hypolipidemic agents, proteins, nucleic acids, agents useful for erythropoiesis stimulation, angiogenesis agents, antiulcer/antireflux agents, and antinauseants/antiemetics, PPAR-alpha agonists, and any combinations thereof.

25. The system according to claim 1, further comprises a beneficial agent including at least one of sodium heparin, LMW heparins, heparoids, hirudin, argatroban, forskolin, vapriprost, prostacyclin and prostacylin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), glycoprotein Iiba/Iia (platelet membrane receptor antagonist antibody), recombinant hirudin, thrombin inhibitors, indomethacin, phenyl salicylate, β

-estradiol, vinblastine, ABT-627 (astrasentan), testosterone, progesterone, paclitaxel, methotrexate, fotemusine, RPR-101511A, cyclosporine A, vincristine, carvediol, vindesine, dipyridamole, methotrexate, folic acid, thrombospondin mimetics, estradiol, dexamethasone, metrizamide, iopamidol, iohexol, iopromide, iobitridol, iomeprol, iopentol, ioversol, ioxilan, iodixanol, iotrolan and any combinations thereof.

26. The system according to claim 1, wherein said medical device is an endovascular medical device.

27. The system according to claim 1, wherein said medical device includes intracoronary medical devices selected from the group consisting of stents, drug delivery catheters, grafts, and drug delivery balloons utilized in subjects'"'"' vasculature.

28. The system according to claim 1, wherein said medical device includes a stent selected from the group consisting of peripheral stents, peripheral coronary stents, degradable coronary stents, non-degradable coronary stents, self-expanding stents, balloon-expanded stents, and esophageal stents.

29. The system according to claim 1, wherein said medical device is selected from the group consisting of arterio-venous grafts, by-pass grafts, penile implants, vascular implants and grafts, intravenous catheters, small diameter grafts, artificial lung catheters, electrophysiology catheters, bone pins, suture anchors, blood pressure and stent graft catheters, breast implants, benign prostatic hyperplasia and prostate cancer implants, bone repair/augmentation devices, breast implants, orthopedic joint implants, dental implants, implanted drug infusion tubes, oncological implants, pain management implants, neurological catheters, central venous access catheters, catheter cuff, vascular access catheters, urological catheters/implants, atherectomy catheters, clot extraction catheters, PTA catheters, PTCA catheters, stylets (vascular and non-vascular), drug infusion catheters, angiographic catheters, hemodialysis catheters, neurovascular balloon catheters, thoracic cavity suction drainage catheters, electrophysiology catheters, stroke therapy catheters, abscess drainage catheters, biliary drainage products, dialysis catheters, central venous access catheters, and parental feeding catheters.

30. The system according to claim 1, wherein said medical device is selected from the group consisting of pacemakers, vascular grafts, sphincter devices, urethral devices, bladder devices, renal devices, gastroenteral and anastomotic devices, vertebral disks, hemostatic barriers, clamps surgical staples/sutures/screws/plates/wires/clips, glucose sensors, blood oxygenator tubing, blood oxygenator membranes, blood bags, birth control/IUDs and associated pregnancy control devices, cartilage repair devices, orthopedic fracture repairs, tissue adhesives, tissue sealants, tissue scaffolds, CSF shunts, dental fracture repair devices, intravitreal drug delivery devices, nerve regeneration conduits, electrostimulation leads, spinal/orthopedic repair devices, wound dressings, embolic protection filters, abdominal aortic aneurysm grafts and devices, neuro aneurysm treatment coils, hemodialysis devices, uterine bleeding patches, anastomotic closures, in vitro diagnostics, aneurysm exclusion devices, neuropatches, vena cava filters, urinary dilators, endoscopic surgical and wound drainings, surgical tissue extractors, transition sheaths and dialators, coronary and peripheral guidewires, circulatory support systems, tympanostomy vent tubes, cerebro-spinal fluid shunts, defibrillator leads, percutaneous closure devices, drainage tubes bronchial tubes, vascular coils, vascular protection devices, vascular intervention devices, including vscular filters and distal supoort devices and emboli filter/entrapment aids, AV access grafts, surgical tampons, drug delivery capsule and cardiac valves.

31. The system according to claim 1, wherein said medical device is selected from the group consisting of atrial septal defect closures, electro-stimulation leads for cardiac rhythm management, tissue and mechanical prosthetic heart valves and rings, arterial-venous shunts, valve annuloplasty devices, mitral valve repair devices, left ventricle assist devices, left atrial appendage filters, cardiac sensors, pacemaker electrodes and leads.

32. The system according to claim 1, wherein said lipophilic agent is continuously delivered to the epicardium and/or pericardial sac.

33. The system according to claim 1, wherein said lipophilic agent comprises zotarolimus having both structures of claim 1.